Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.52 |
| ▸ | CTSB | P07858 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29593402 | 1.00 | MAPK14 (0.52) | MAPK14CTSBMAPTMAPK1MEN1 | |
| SCHEMBL29537119 | 0.82 | MAPK14 (0.57) | MAPK14MAPK1MAPK8 | |
| SCHEMBL13239748 | 0.82 | MAPK14 (0.57) | MAPK14MAPK1MAPK8 | |
| SCHEMBL5116423 | 0.79 | MAPK14 (0.46) | MAPK14MAPK1MAPK8 | |
| SCHEMBL5110605 | 0.77 | MAPK14 (0.46) | MAPK14MAPK1MAPK8 | |
| SCHEMBL5122277 | 0.77 | MAPK14 (0.53) | MAPK14MAPK1MAPK8 | |
| SCHEMBL22139066 | 0.77 | MAPK14 (0.60) | MAPK14MAPK1MAPK8 | |
| SCHEMBL5112933 | 0.75 | MAPK14 (0.47) | MAPK14MAPK1MAPK8 | |
| SCHEMBL1351776 | 0.74 | KMT2A (0.47) | CTSBMAPTMEN1KMT2APPARG | |
| SCHEMBL14266291 | 0.73 | MAPK14 (0.56) | MAPK14MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159212-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| EP-3691620-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190105312-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2019-04-11 | — | — | US | disclosed |
| WO-2019071147-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20190105311-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2019-04-11 | — | — | US | disclosed |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN J | 2007-06-14 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1361880-B1 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| US-20040116698-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN JEFFREY (US) | 2004-06-17 | — | — | US | disclosed |
| US-6696566-B2 | SELECTIVE P38 KINASE INHIBITORS RELATIVE TO CYCLIN-DEPENDENT KINASES AND TYROSINE KINASES | SYNTEX (U.S.A.) LLC | 2004-02-24 | — | — | US | disclosed |
| EP-1361880-A2 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-19 | — | — | EP | disclosed |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | SYNTEX (U.S.A.) LLC | 2003-09-11 | — | — | US | disclosed |
| WO-2002064594-A2 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885CTSB 3569/4885MAPT 1513/4885 |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, RHOXF2 | MAPK14 193/4885CTSB 3753/4885MAPT 1663/4885 |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | P2RX6, P2RX1, P2RX7 | MAPK14 4250/4885CTSB 4362/4885MAPT 3318/4885 |
| US-20190105311-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 196/4885CTSB 3242/4885MAPT 1537/4885 |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885CTSB 3569/4885MAPT 1513/4885 |
| US-20190105312-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885CTSB 3569/4885MAPT 1513/4885 |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885CTSB 3569/4885MAPT 1513/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885CTSB 3569/4885MAPT 1513/4885 |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | ARRB1, MAPK1, MAPK8 | MAPK14 64/4885CTSB 4301/4885MAPT 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.